Ovid Therapeutics, Inc. (OVID)
2.375
-0.10
(-3.85%)
USD |
NASDAQ |
Oct 22, 16:00
2.375
0.00 (0.00%)
After-Hours: 20:00
Ovid Therapeutics Enterprise Value : 351.84M for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 351.84M |
| October 20, 2026 | 331.52M |
| October 19, 2026 | 296.42M |
| October 16, 2026 | 292.72M |
| October 15, 2026 | 313.04M |
| October 14, 2026 | 300.11M |
| October 13, 2026 | 300.11M |
| October 12, 2026 | 340.76M |
| October 09, 2026 | 350.00M |
| October 08, 2026 | 327.82M |
| October 07, 2026 | 331.52M |
| October 06, 2026 | 333.37M |
| October 05, 2026 | 327.82M |
| October 02, 2026 | 335.21M |
| October 01, 2026 | 344.45M |
| September 30, 2026 | 355.54M |
| September 29, 2026 | 364.78M |
| September 28, 2026 | 350.00M |
| September 25, 2026 | 338.91M |
| September 24, 2026 | 356.46M |
| September 23, 2026 | 370.32M |
| September 22, 2026 | 405.42M |
| September 21, 2026 | 396.18M |
| September 18, 2026 | 392.49M |
| September 17, 2026 | 394.34M |
| Date | Value |
|---|---|
| September 16, 2026 | 390.64M |
| September 15, 2026 | 396.18M |
| September 14, 2026 | 401.73M |
| September 11, 2026 | 392.49M |
| September 10, 2026 | 381.40M |
| September 09, 2026 | 394.34M |
| September 08, 2026 | 403.57M |
| September 04, 2026 | 412.81M |
| September 03, 2026 | 409.12M |
| September 02, 2026 | 396.18M |
| September 01, 2026 | 405.42M |
| August 31, 2026 | 388.79M |
| August 28, 2026 | 412.81M |
| August 27, 2026 | 436.83M |
| August 26, 2026 | 427.59M |
| August 25, 2026 | 433.14M |
| August 24, 2026 | 416.51M |
| August 21, 2026 | 412.81M |
| August 20, 2026 | 401.73M |
| August 19, 2026 | 436.83M |
| August 18, 2026 | 420.20M |
| August 17, 2026 | 429.44M |
| August 14, 2026 | 418.35M |
| August 13, 2026 | 412.81M |
| August 12, 2026 | 379.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.593B |
| Alnylam Pharmaceuticals, Inc. | 29.78B |
| Anika Therapeutics, Inc. | 262.53M |
| Savara, Inc. | 816.59M |
| Vericel Corp. | 2.027B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.01M |
| Revenue (Quarterly) | 0.733M |
| Total Expenses (Quarterly) | 15.74M |
| EPS Diluted (Quarterly) | -0.076 |
| Gross Profit Margin (Quarterly) | 97.82% |
| Profit Margin (Quarterly) | -2.05K% |
| Earnings Yield | -10.67% |
| Normalized Earnings Yield | -3.095 |